The Combined Expression of the Nonstructural Protein NS1 and the N-Terminal Half of NS2 (NS2 <sub>1-180</sub> ) by ChAdOx1 and MVA Confers Protection against Clinical Disease in Sheep upon Bluetongue Virus Challenge
Sergio Utrilla-Trigo, Luis Jiménez-Cabello, Eva Calvo-Pinilla, Alejandro Marín-López, Gema Lorenzo, Pedro Sánchez-Cordón, Sandra Moreno, Julio Benavides, Sarah Gilbert, Aitor Nogales, Javier Ortego
Abstract
Current BTV vaccines are effective but they do not allow to distinguish between vaccinated and infected animals (DIVA strategy) and are serotype specific. In this work we have develop a DIVA multiserotype vaccination strategy based on adenoviral (ChAdOx1) and MVA vaccine vectors, the most widely used in current phase I and II clinical trials, and the conserved nonstructural BTV proteins NS1 and NS2. This immunization strategy solves the major drawbacks of the current marketed vaccines.
Topics & Concepts
BiologyVirologyViremiaVirusVaccinationOrbivirusImmunizationSerotypeVacciniaImmunogenicityDivaDuck embryo vaccineViral vectorCytotoxic T cellVector (molecular biology)Viral loadPathogenDiseaseImmunologyModified vaccinia AnkaraReoviridaeBooster doseVector-Borne Animal DiseasesVirology and Viral DiseasesAnimal Disease Management and Epidemiology